Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy
about
Pharmacogenomics in Pediatric Patients: Towards Personalized MedicineWarfarin genotyping with hybridization-induced aggregation on a poly(ethylene terephthalate) microdevice.VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients.UNUSUAL WARFARIN DOSE TO ACHIEVE THERAPEUTIC INR IN A 4-MONTH OLD CHILD: NON-GENETICS RISK FACTORS ARE STILL A CHALLENGE.The rs2108622 polymorphism is related to the early risk of ischemic stroke in non-valvular atrial fibrillation subjects under oral anticoagulation.Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists.Correlation between Rs2108622 Locus of CYP4F2 Gene Single Nucleotide Polymorphism and Warfarin Dosage in Iranian Cardiovascular Patients.Patient Decisions to Receive Secondary Pharmacogenomic Findings and Development of a Multidisciplinary Practice Model to Integrate Results Into Patient Care.Stereospecific Metabolism of R- and S-Warfarin by Human Hepatic Cytosolic Reductases.Evaluation of CYP2C9- and VKORC1-based pharmacogenetic algorithm for warfarin dose in Gaza-Palestine.Creating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patientsEstablishment of a Han Chinese-specific pharmacogenetic-guided warfarin dosing algorithm
P2860
Q28071448-4F9F35CD-01FF-4896-AA57-3AC6C5B7E5D1Q30275196-C9F6E00A-007F-4159-B1F6-0D4CAD266425Q37552063-FD0E1B18-A637-4146-845E-96DE2BAFAA58Q47160906-896B9EEA-BB2D-4650-98D2-D0B3B60236BAQ47256147-6CB1F980-0A5C-497B-85C9-90C912F0DC65Q47728750-A38B90D5-4AD8-416B-B061-0B05C83F0E66Q49892570-04B57B18-17E0-4903-BB6C-5BD0EB706855Q49951884-FC8018EF-2A69-459E-AD3E-8EE825EAC5C3Q54158178-138F5144-CAD8-4302-A890-97642552D551Q55379283-844747B8-404C-49F5-98FF-FF1F32E53DCDQ58558658-11AECECC-D3B0-4C72-9884-394E9B06649DQ58759165-CCD32219-DABB-451D-855D-26196ECFDE08
P2860
Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Clinical Practice Recommendati ...... 1 Variants in Warfarin Therapy
@ast
Clinical Practice Recommendati ...... 1 Variants in Warfarin Therapy
@en
Clinical Practice Recommendati ...... 1 Variants in Warfarin Therapy
@nl
type
label
Clinical Practice Recommendati ...... 1 Variants in Warfarin Therapy
@ast
Clinical Practice Recommendati ...... 1 Variants in Warfarin Therapy
@en
Clinical Practice Recommendati ...... 1 Variants in Warfarin Therapy
@nl
prefLabel
Clinical Practice Recommendati ...... 1 Variants in Warfarin Therapy
@ast
Clinical Practice Recommendati ...... 1 Variants in Warfarin Therapy
@en
Clinical Practice Recommendati ...... 1 Variants in Warfarin Therapy
@nl
P2093
P50
P3181
P1476
Clinical Practice Recommendati ...... 1 Variants in Warfarin Therapy
@en
P2093
Jacques Turgeon
Kaitlyn Shaw
Lawrence J Lesko
Richard B Kim
Shinya Ito
Soomi Hwang
Ursula Amstutz
Veronique Michaud
P304
P3181
P356
10.1097/FTD.0000000000000192
P407
P577
2015-08-01T00:00:00Z